Industrial - Machinery
Compare Stocks
5 / 10Stock Comparison
RRX vs AME vs ROK vs HON vs EMR
Revenue, margins, valuation, and 5-year total return — side by side.
Industrial - Machinery
Industrial - Machinery
Conglomerates
Industrial - Machinery
RRX vs AME vs ROK vs HON vs EMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Machinery | Industrial - Machinery | Industrial - Machinery | Conglomerates | Industrial - Machinery |
| Market Cap | $13.73B | $53.72B | $50.37B | $136.91B | $79.02B |
| Revenue (TTM) | $6.00B | $7.60B | $8.80B | $36.76B | $18.32B |
| Net Income (TTM) | $287M | $1.53B | $1.09B | $4.10B | $2.44B |
| Gross Margin | 37.5% | 36.6% | 52.5% | 36.9% | 52.7% |
| Operating Margin | 11.3% | 26.2% | 19.1% | 14.9% | 19.8% |
| Forward P/E | 19.3x | 29.1x | 36.9x | 20.5x | 21.7x |
| Total Debt | $5.06B | $2.28B | $3.65B | $34.58B | $13.76B |
| Cash & Equiv. | $522M | $458M | $468M | $12.49B | $1.54B |
RRX vs AME vs ROK vs HON vs EMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Regal Rexnord Corpo… (RRX) | 100 | 259.3 | +159.3% |
| AMETEK, Inc. (AME) | 100 | 255.7 | +155.7% |
| Rockwell Automation… (ROK) | 100 | 207.4 | +107.4% |
| Honeywell Internati… (HON) | 100 | 148.1 | +48.1% |
| Emerson Electric Co. (EMR) | 100 | 231.2 | +131.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RRX vs AME vs ROK vs HON vs EMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RRX ranks third and is worth considering specifically for value.
- Lower P/E (19.3x vs 21.7x)
AME is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 6.6%, EPS growth 7.9%, 3Y rev CAGR 6.4%
- 423.4% 10Y total return vs ROK's 341.0%
- Lower volatility, beta 0.93, Low D/E 21.5%, current ratio 1.06x
- PEG 2.60 vs HON's 11.18
ROK is the #2 pick in this set and the best alternative if momentum and efficiency is your priority.
- +60.2% vs HON's +2.8%
- 9.7% ROA vs RRX's 2.1%, ROIC 15.1% vs 4.5%
HON carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 15 yrs, beta 0.74, yield 2.1%
- Beta 0.74, yield 2.1%, current ratio 1.32x
- 7.8% revenue growth vs RRX's -1.6%
- Beta 0.74 vs RRX's 1.91
Among these 5 stocks, EMR doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.8% revenue growth vs RRX's -1.6% | |
| Value | Lower P/E (19.3x vs 21.7x) | |
| Quality / Margins | 20.1% margin vs RRX's 4.8% | |
| Stability / Safety | Beta 0.74 vs RRX's 1.91 | |
| Dividends | 2.1% yield, 15-year raise streak, vs EMR's 1.5% | |
| Momentum (1Y) | +60.2% vs HON's +2.8% | |
| Efficiency (ROA) | 9.7% ROA vs RRX's 2.1%, ROIC 15.1% vs 4.5% |
RRX vs AME vs ROK vs HON vs EMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
RRX vs AME vs ROK vs HON vs EMR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AME leads in 1 of 6 categories
RRX leads 1 • ROK leads 1 • HON leads 0 • EMR leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
AME leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HON is the larger business by revenue, generating $36.8B annually — 6.1x RRX's $6.0B. AME is the more profitable business, keeping 20.1% of every revenue dollar as net income compared to RRX's 4.8%. On growth, ROK holds the edge at +11.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $6.0B | $7.6B | $8.8B | $36.8B | $18.3B |
| EBITDAEarnings before interest/tax | $1.2B | $2.3B | $1.9B | $6.5B | $4.7B |
| Net IncomeAfter-tax profit | $287M | $1.5B | $1.1B | $4.1B | $2.4B |
| Free Cash FlowCash after capex | $805M | $1.7B | $1.3B | $4.2B | $3.1B |
| Gross MarginGross profit ÷ Revenue | +37.5% | +36.6% | +52.5% | +36.9% | +52.7% |
| Operating MarginEBIT ÷ Revenue | +11.3% | +26.2% | +19.1% | +14.9% | +19.8% |
| Net MarginNet income ÷ Revenue | +4.8% | +20.1% | +12.4% | +11.2% | +13.3% |
| FCF MarginFCF ÷ Revenue | +13.4% | +22.4% | +15.2% | +11.4% | +17.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.3% | +11.3% | +11.8% | -6.9% | +2.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +11.6% | +14.5% | +39.6% | -41.9% | +28.2% |
Valuation Metrics
RRX leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 29.4x trailing earnings, HON trades at a 50% valuation discount to ROK's 58.5x P/E. Adjusting for growth (PEG ratio), AME offers better value at 3.28x vs HON's 15.99x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $13.7B | $53.7B | $50.4B | $136.9B | $79.0B |
| Enterprise ValueMkt cap + debt − cash | $18.3B | $55.5B | $53.6B | $159.0B | $91.2B |
| Trailing P/EPrice ÷ TTM EPS | 48.88x | 36.64x | 58.45x | 29.36x | 34.92x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.31x | 29.08x | 36.93x | 20.52x | 21.71x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.28x | — | 15.99x | 7.73x |
| EV / EBITDAEnterprise value multiple | 15.40x | 29.55x | 30.64x | 19.99x | 18.07x |
| Price / SalesMarket cap ÷ Revenue | 2.31x | 7.26x | 6.04x | 3.66x | 4.39x |
| Price / BookPrice ÷ Book value/share | 2.00x | 5.10x | 13.66x | 9.00x | 3.94x |
| Price / FCFMarket cap ÷ FCF | 15.37x | 32.14x | 37.09x | 25.39x | 29.63x |
Profitability & Efficiency
ROK leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ROK delivers a 29.6% return on equity — every $100 of shareholder capital generates $30 in annual profit, vs $4 for RRX. AME carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to HON's 2.24x. On the Piotroski fundamental quality scale (0–9), ROK scores 8/9 vs HON's 6/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.2% | +14.4% | +29.6% | +23.1% | +12.1% |
| ROA (TTM)Return on assets | +2.1% | +9.6% | +9.7% | +5.3% | +5.8% |
| ROICReturn on invested capital | +4.5% | +12.1% | +15.1% | +12.6% | +8.2% |
| ROCEReturn on capital employed | +5.4% | +15.0% | +18.5% | +12.6% | +10.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 8 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.74x | 0.21x | 0.98x | 2.24x | 0.68x |
| Net DebtTotal debt minus cash | $4.5B | $1.8B | $3.2B | $22.1B | $12.2B |
| Cash & Equiv.Liquid assets | $522M | $458M | $468M | $12.5B | $1.5B |
| Total DebtShort + long-term debt | $5.1B | $2.3B | $3.6B | $34.6B | $13.8B |
| Interest CoverageEBIT ÷ Interest expense | 2.04x | 23.34x | 9.06x | 3.92x | 6.46x |
Total Returns (Dividends Reinvested)
Evenly matched — ROK and EMR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ROK five years ago would be worth $17,462 today (with dividends reinvested), compared to $10,326 for HON. Over the past 12 months, ROK leads with a +60.2% total return vs HON's +2.8%. The 3-year compound annual growth rate (CAGR) favors EMR at 20.7% vs HON's 5.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +41.4% | +12.3% | +12.8% | +10.9% | +4.3% |
| 1-Year ReturnPast 12 months | +59.9% | +38.9% | +60.2% | +2.8% | +30.4% |
| 3-Year ReturnCumulative with dividends | +62.0% | +64.1% | +65.0% | +16.2% | +75.9% |
| 5-Year ReturnCumulative with dividends | +46.6% | +74.5% | +74.6% | +3.3% | +59.5% |
| 10-Year ReturnCumulative with dividends | +257.1% | +423.4% | +341.0% | +135.1% | +206.6% |
| CAGR (3Y)Annualised 3-year return | +17.4% | +18.0% | +18.2% | +5.1% | +20.7% |
Risk & Volatility
Evenly matched — ROK and HON each lead in 1 of 2 comparable metrics.
Risk & Volatility
HON is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than RRX's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ROK currently trades 96.7% from its 52-week high vs EMR's 85.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 0.93x | 1.33x | 0.74x | 1.52x |
| 52-Week HighHighest price in past year | $236.34 | $243.18 | $463.49 | $248.18 | $165.15 |
| 52-Week LowLowest price in past year | $124.73 | $168.49 | $277.66 | $186.76 | $108.37 |
| % of 52W HighCurrent price vs 52-week peak | +87.3% | +96.4% | +96.7% | +87.1% | +85.4% |
| RSI (14)Momentum oscillator 0–100 | 68.2 | 63.3 | 74.9 | 45.1 | 61.3 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.2M | 831K | 3.7M | 2.8M |
Analyst Outlook
Evenly matched — HON and EMR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: RRX as "Buy", AME as "Buy", ROK as "Hold", HON as "Buy", EMR as "Buy". Consensus price targets imply 14.8% upside for EMR (target: $162) vs -2.6% for ROK (target: $437). For income investors, HON offers the higher dividend yield at 2.14% vs AME's 0.53%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $217.50 | $245.91 | $436.56 | $243.83 | $161.92 |
| # AnalystsCovering analysts | 22 | 29 | 39 | 28 | 41 |
| Dividend YieldAnnual dividend ÷ price | +0.7% | +0.5% | +1.2% | +2.1% | +1.5% |
| Dividend StreakConsecutive years of raises | 1 | 16 | 20 | 15 | 37 |
| Dividend / ShareAnnual DPS | $1.40 | $1.23 | $5.23 | $4.63 | $2.10 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.8% | +0.8% | +2.8% | +1.6% |
AME leads in 1 of 6 categories (Income & Cash Flow). RRX leads in 1 (Valuation Metrics). 3 tied.
RRX vs AME vs ROK vs HON vs EMR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RRX or AME or ROK or HON or EMR a better buy right now?
For growth investors, Honeywell International Inc.
(HON) is the stronger pick with 7. 8% revenue growth year-over-year, versus -1. 6% for Regal Rexnord Corporation (RRX). Honeywell International Inc. (HON) offers the better valuation at 29. 4x trailing P/E (20. 5x forward), making it the more compelling value choice. Analysts rate Regal Rexnord Corporation (RRX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RRX or AME or ROK or HON or EMR?
On trailing P/E, Honeywell International Inc.
(HON) is the cheapest at 29. 4x versus Rockwell Automation, Inc. at 58. 5x. On forward P/E, Regal Rexnord Corporation is actually cheaper at 19. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: AMETEK, Inc. wins at 2. 60x versus Honeywell International Inc. 's 11. 18x.
03Which is the better long-term investment — RRX or AME or ROK or HON or EMR?
Over the past 5 years, Rockwell Automation, Inc.
(ROK) delivered a total return of +74. 6%, compared to +3. 3% for Honeywell International Inc. (HON). Over 10 years, the gap is even starker: AME returned +423. 4% versus HON's +135. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RRX or AME or ROK or HON or EMR?
By beta (market sensitivity over 5 years), Honeywell International Inc.
(HON) is the lower-risk stock at 0. 74β versus Regal Rexnord Corporation's 1. 91β — meaning RRX is approximately 158% more volatile than HON relative to the S&P 500. On balance sheet safety, AMETEK, Inc. (AME) carries a lower debt/equity ratio of 21% versus 2% for Honeywell International Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RRX or AME or ROK or HON or EMR?
By revenue growth (latest reported year), Honeywell International Inc.
(HON) is pulling ahead at 7. 8% versus -1. 6% for Regal Rexnord Corporation (RRX). On earnings-per-share growth, the picture is similar: Regal Rexnord Corporation grew EPS 43. 5% year-over-year, compared to -15. 5% for Honeywell International Inc.. Over a 3-year CAGR, EMR leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RRX or AME or ROK or HON or EMR?
AMETEK, Inc.
(AME) is the more profitable company, earning 20. 0% net margin versus 4. 7% for Regal Rexnord Corporation — meaning it keeps 20. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AME leads at 26. 2% versus 11. 5% for RRX. At the gross margin level — before operating expenses — EMR leads at 52. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RRX or AME or ROK or HON or EMR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, AMETEK, Inc. (AME) is the more undervalued stock at a PEG of 2. 60x versus Honeywell International Inc. 's 11. 18x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Regal Rexnord Corporation (RRX) trades at 19. 3x forward P/E versus 36. 9x for Rockwell Automation, Inc. — 17. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EMR: 14. 8% to $161. 92.
08Which pays a better dividend — RRX or AME or ROK or HON or EMR?
All stocks in this comparison pay dividends.
Honeywell International Inc. (HON) offers the highest yield at 2. 1%, versus 0. 5% for AMETEK, Inc. (AME).
09Is RRX or AME or ROK or HON or EMR better for a retirement portfolio?
For long-horizon retirement investors, AMETEK, Inc.
(AME) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93), 0. 5% yield, +423. 4% 10Y return). Regal Rexnord Corporation (RRX) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AME: +423. 4%, RRX: +257. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RRX and AME and ROK and HON and EMR?
Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.